Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines and Commercial Opportunities : Market Research Report

Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines and Commercial Opportunities

Published: Apr. 1, 2006 - 369 Pages

List of Tables
List of Figures
List of Abbreviations
Executive Summary: Objective of the Report; Research Methodology
Chapter 1. Introduction to Cancer: Epidemiology, Pathophysiology, Diagnosis, and Treatment: Cancer Epidemiology
Chapter 2. Drug Development Challenges: Tumour Biology
Chapter 3. Chemotherapeutic Treatment Options: Clinical Management and Drug Development Issues: Current Chemotherapies
Chapter 4. The Market for Cancer Chemotherapies: The Market for Chemotherapies
Chapter 5. Chemotherapies in Research and Development: General Trends in Global Oncology Markets Considered to Impact Chemotherapies in Research and Development
Chapter 6: Cancer Research - Evaluating Drug Development and Market Opportunities: Current Themes and Trends in Cancer Research
Chapter 7. Companies Developing Cancer Drugs: Leading Companies and Oncology Pipelines; Leading Multinational Companies and Oncology Products; Reference Sources
List of Tables: Table 1.1 Highest Mortality Rates for Common Cancers; Table 1.2 Common Cancers in the United Kingdom Relative to Gender, 2004; Table 1.3 Incidence Trends for the Common Cancers in the United Kingdom (1990-2001); Table 1.4 Mortality Rates in the United Kingdom, 2003; Table 1.5 Changes in 5- and 10-Year Survival Rates for Common Cancers, United Kingdom (1971-1999 Diagnosis); Table 1.6 Incidence Rates for Common Cancers in the United States and United Kingdom; Table 1.7 Incidence and Mortality for Most Prevalent Cancer in the United States, 2005 Estimates for Men and Women; Table 1.8 Trends in Cancer Incidence, 2005 (% Total New Cases); Table 1.9 Incidence, Mortality, Survival Trends, and Risk Factors for 10 Less Common Cancers in the United States; Table 1.10 Chemotherapy Options for Common Solid Tumour Malignancies by Disease Stage; Table 2.1 Viruses Implicated in Human Cancers; Table 2.2 Genes Most Commonly Identified in Human Cancers; Table 2.3 Genes Most Commonly Implicated in Major Human Cancers; Table 2.4 Chemotherapy Drugs Most Commonly Used to Treat Cancer; Table 3.1 General Staging Criteria Relevant to Chemotherapy Treatment Options in Solid Tumour Malignancies; Table 3.2 Chemotherapy Drugs Most Commonly Used to Treat Lung Cancer; Table 3.3 Most Common Treatment Options for Limited Small Cell Lung Carcinoma; Table 3.4 Most Common Treatment Options for Extensive Small Cell Lung Carcinoma; Table 3.5 Less Common Treatment Protocols for Extensive Small Cell Lung Carcinoma; Table 3.6 Most Common Treatment Protocols for Nonsmall Cell Lung Carcinoma; Table 3.7 Experimental Chemotherapy for Advanced Lung Cancer; Table 3.8 Chemotherapy Drugs Most Commonly Used to Treat Colorectal Cancer; Table 3.9 Breast Cancer Chemotherapy Treatment Options; Table 3.10 Hormonal Therapies Used in the Treatment of Advanced Prostate Cancer; Table 3.11 Chemotherapy Drugs Most Commonly Used to Treat Ovarian Cancer; Table 3.12 Second-Line Treatments for Ovarian Cancer; Table 3.13 First-Line Combined Treatment Options for Advanced Ovarian Cancer; Table 3.14 Second-Line Combined Treatment Options for Resistant Ovarian Cancer; Table 3.15 Combined Chemotherapy Treatment Protocols for Acute Myeloid Leukaemia; Table 3.16 Common Drugs Used to Treat Chronic Myeloid Leukaemia; Table 3.17 Standard Treatment Options for Chronic Lymphocytic Leukaemia; Table 3.18 Standard Treatment Options for Hodgkin’s Disease; Table 3.19 Treatment Options for Advanced Low-Grade Non-Hodgkin’s Lymphoma; Table 3.20 Treatment Options for Early-Stage Fast-Growing Non-Hodgkin’s Lymphoma; Table 3.21 Chemotherapy Drugs Approved by the United States Food and Drug Administration; Table 3.22 Drugs Administered to Combat Dose-Limiting Side Effects of Chemotherapy; Table 4.1 Estimated Global Sales (US$) and Forecasts of Leading Cancer Chemo- therapies, 2005-; Table 4.2 Approximate 2004 Expenditures for Chemotherapy Treatment of the Most Common Cancers Based on Incidence Rates; Table 4.3 Comparative Assessment of Positive Outcomes and Problems in Healthcare Systems, United States/United Kingdom; Table 4.4 Accessibilty Ratings to New Cancer Drugs in Europe by Country; Table 4.5 Global Incidence and Mortality Ratios for the Most Common Cancers by Gender; Table 4.6 Global Incidence of Cancer by Site, Males and Females; Table 4.7 Estimated Percentage of Cancer Cases by Type in Men and Women, United States, 2005; Table 4.8 Predicted Average Lifetime Risk for Developing Cancer in Men and Women, 1999-2001 Estimates; Table 4.9 Five-Year Relative Survival Rates for the Most Common Cancers, United States, 1995-2000; Table 4.10 Comparison of 5-Year Survival Rates (%) for Most Common Cancers Over Three Time Periods, United States; Table 4.11 Death Rates from the Most Common Cancers in Men and Women, United States, 2005 Estimates; Table 4.12 New Anticancer Drugs with Strong Commercial Outlook Based on Clinical Efficacy; Table 5.1 New Drug Application Submissions (Oncology), United States Food and Drug Administration, 2005; Table 5.2 Comparison of Angiogenesis Inhibitors; Table 5.3 Major Projected Competitors: Oncology Drugs for Advanced Colon Cancer that Target Growth Factor Signal Pathways; Table 5.4 Tykerb: Summary of Clinical Trial Studies; Table 5.5 Late-Stage Oncology Products in Clinical Development Grouped by Mechanism of Action; Table 5.6 GlaxoSmithKline’s Portfolio of Oncology Products in Research and Development; Table 5.7 Histone Deacetylase Inhibitors in Clinical Trials, 2006; Table 5.8 Biotechnological Oncology Products in Clinical Development by Clinical Phase; Table 5.9 Top Prospects for Market Success in the Oncology Pipeline; Table 6.1 United States Federal Drug Administration Approved and Investigational Monoclonal Antibody Therapeutics for Cancer; Table 6.2 Small Molecule Cancer Therapeutics in Research and Development by Clinical Phase; Table 6.3 Novel Druggable Tumour Targets in Research and Development; Table 6.4 Antisense Therapeutics in Research and Development; Table 7.1 The Top 50 Global Pharmaceutical Companies (2004 and 2005 Revenues); Table 7.2 Global Portfolio Revenues and Market Share of Cancer Chemotherapies, 2005 (US$m); Table 7.3 Roche`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.4 Novartis` Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.5 Sanofi-Aventis` Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.6 AstraZeneca`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.7 Eli Lilly’s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.8 GlaxoSmithKline`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.9 Pfizer`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.10 Bristol-Myers Squibb`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.11 Schering-Plough`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.12 Johnson & Johnson`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.13 Amgen`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.14 Genentech`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m); Table 7.15 Additional Discovery and Development Companies Specializing in Oncology Therapeutics
List of Figures: Figure 1.1 Total Cancer Mortality (Age Standardized Rates); Figure 1.2 Total Cancer Incidence (Age Standardized Rates); Figure 1.3 Averaged Incidence of the Most Common Cancers in the United Kingdom for Men and Women; Figure 1.4 Incidence and Mortality of the 10 Most Common Cancers in the United States, 2005 Estimates; Figure 1.5 Lung Cancer Incidence (Age Standardized Rates); Figure 1.6 Colon Cancer Incidence (Age Standardized Rates); Figure 1.7 Breast Cancer Incidence/Mortality (Age Standardized Rates); Figure 1.8 Prostate Cancer Incidence/Mortality (Age Standardized Rates); Figure 1.9 Bladder Cancer Incidence (Age Standardized Rates); Figure 1.10 Stomach Cancer Incidence (Age Standardized Rates); Figure 1.11 Cervical Cancer Incidence/Mortality (Age Standardized Rates); Figure 1.12 Melanoma Incidence (Age Standardized Rates); Figure 1.13 Larynx Cancer Incidence (Age Standardized Rates); Figure 1.14 Hodgkin’s Disease Incidence (Age Standardized Rates); Figure 1.15 Non-Hodgkin’s Lymphoma Incidence (Age Standardized Rates); Figure 1.16 Ovarian Cancer Incidence/Mortality (Age Standardized Rates); Figure 1.17 Chemotherapy Regimens Used to Treat Non-Hodgkin’s Lymphoma; Figure 2.1 Origins of Chemotherapy Resistance; Figure 2.2 Pharmacological Parameters of Drug Resistance; Figure 2.3 Proliferative Cell Cycle: Genes and Drug Targets; Figure 3.1 Factors Associated with Successful Chemotherapy Outcome; Figure 4.1 Best-Selling Chemotherapies, 2005 (US$m); Figure 4.2 Market Share of the Top 10 Cancer Chemotherapies, 2005 & 2010; Figure 4.3 Growth Rates of Best-Selling Cancer Chemotherapy Drugs, 2005; Figure 4.4 Total Healthcare Costs: % Gross Domestic Product (GDP) by Country (2002); Figure 4.5 Key Parameters of Cancer Drug Market; Figure 5.1 Therapeutic Classes of Oncology Drugs in the Product Pipeline; Figure 6.1 General Clinical Research Areas in Cancer Therapeutics; Figure 6.2 General Categories Of Therapeutic Enhancement Approaches; Figure 6.3 Biotechnology Approaches to Cancer Therapeutic Research and Development; Figure 6.4 Types of Therapeutic Cancer Vaccines in Clinical Research and Development; Figure 6.5 Tumour Antigen Targets Used in the Development of Therapeutic Cancer Vaccines; Figure 6.6 Monoclonal Antibody Therapeutic Targets; Figure 6.7 Small Molecule Therapy Targets; Figure 6.8 Combined Chemotherapy Treatment Possibilities; Figure 6.9 Cell Targets of Experimental Cancer Therapeutics: Drugs and Delivery Mode; Figure 7.1 Leading Oncology Companies by Chemotherapy Portfolio Revenues, 2005 (US$m)

Abstract

This comprehensive report is designed to present a state-of-the-art view of chemotherapy approaches to the treatment of cancer and an assessment of the critical parameters of drug discovery and development that may lead to the introduction of new oncology drugs with great therapeutic and market potential over the next decade. The oncology market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade. Currently, there are 25 million people afflicted with cancer worldwide, and the World Health Organization (WHO) predicts that cancer rates may increase by 50% from 10 million cases in 2000 to 15 million cases in 2015. Moreover, the Association for International Cancer Research (AICR) estimates that by 2020, there will be 10 million deaths from cancer. Even in developed nations, approximately 50% of patients diagnosed with cancer will eventually die of this disease. The challenges are great, but the world of molecular medicine and biopharmaceuticals has presented great opportunities to discover and develop new pharmacological approaches with prospects for greater therapeutic efficacy and more promising clinical outcome.

In this report, Chemotherapy Market Insights, 2006-2016: A Critical Analysis of CancerResearch, Treatments, Pipelines, and Commercial Opportunities, the reader will be presented with an expert perspective on oncology therapeutics, drug development, and commercial opportunities within the field. The introductory chapter is designed to provide a global perspective on the many facets of cancer that will affect the discovery, development and marketing of oncology pharmaceuticals over the next decade. Among the critical disease parameters are the global epidemiology of cancer, which includes current incidence, survival and mortality trends for the most common cancers worldwide. This assessment is designed to focus attention on the types of cancer that may be most appropriately targeted for treatment research and development based on these current global statistics.

These statistics also highlight the types of cancer that continue to be most refractory to current treatment approaches, suggesting areas for future research in drug discovery. Each of the many common cancers is assessed in this chapter with respect to its aetiology, pathophysiology, diagnosis, current treatment options, and clinical outcomes.

Objectives of the Report

The objectives of this report are to provide an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, pipeline programs, and innovating companies and products. It is hoped that the reader will benefit from critical review, market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/15/2012 - 30

Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines and Commercial Opportunities

Table of Contents

Abstract